Skip to content

Comparison of effect of Licorice vaginal cream with Clotrimazol vaginal cream in candida vaginitis treatment

Comparison of effect of Licorice vaginal cream with Clotrimazol vaginal cream in candida vaginitis treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016032511360N2
Enrollment
65
Registered
2016-05-03
Start date
2008-04-03
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Candida Vaginitis. Candidiasis of Vulva and Vagina

Interventions

Intervention 1: Treatment with vaginal cream Licorice 2%- Built in the Pharmacy School of Ahvaz Jundishapur University of Medical Sciences-one applicator every night for a week-Intervention group. I
Treatment - Drugs
Treatment with vaginal cream Licorice 2%- Built in the Pharmacy School of Ahvaz Jundishapur University of Medical Sciences-one applicator every night for a week-Intervention group
Treatment with vaginal cream Clotrimazole 1%- production of Pars darou company-an applicator every night for a week-control group

Sponsors

Vice-chancellor for Research, Jondishapour University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: signs and symptoms of Candida vaginitis, positive direct smear of vaginal discharge Exclusion criteria: pregnant women, low compliance, any drug hypersensitivity, recurrent Candida vaginitis (4 or more Candida vaginitis in a year), consumption of immunosuppressive drug or widespread antibiotics, history of epilepsy, diabetes, heart disease, high blood pressure, thyroid diseases, or advanced arthritis, using other vaginal creams or suppositories during the study period, consumption of systemic antifungal drugs during 4 weeks prior to the study, presence of non-candidal vaginitis, consumption of oral contraceptives.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Discharge. Timepoint: Baseline, 1&2 week after treatment. Method of measurement: Clinical Examination, observation, and medical history.;Pruritus. Timepoint: Baseline, 1&2 week after treatment. Method of measurement: History.;Erythema symptoma. Timepoint: Baseline, 1&2 week after treatment. Method of measurement: Clinical Examination, Observation, and History.;Dysuria Symptom. Timepoint: Baseline, 1&2 week after treatment. Method of measurement: History.;Dysparonia Symptom. Timepoint: Baseline, 1&2 week after treatment. Method of measurement: History.;Wet Smear and Vaginal Culture results. Timepoint: Baseline, 1&2 week after treatment. Method of measurement: Wet Smear and Vaginal Culture.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Mina Iravani

Jondishapour University of Medical Sciences

minairavani2004@yahoo.com;iravani-m@ajums.ac.ir+98 61 3373 8331

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026